Jayoung Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jayoung Han has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Dongwoo Ko
College of Business, Hankuk University of Foreign Studies, Seoul, Korea
3 shared publications - Yuan Fang
Department of Pharmaceutical Sciences, Binghamton University School of Pharmacy and Pharmaceutical Sciences, NY
2 shared publications Dania Tawam
Fairleigh Dickinson University School of Pharmacy and Health Sciences
1 shared publicationDarlingtina Esiaka
Center for Health, Engagement and Transformation and Department of Behavioral Science, University of Kentucky College of Medicine
1 shared publication- Elizabeth J. Unni
Touro College of Pharmacy, New York, USA
1 shared publication Gina No
School of Pharmacy and Health Sciences, Fairleigh Dickinson University, USA
1 shared publication
Latest Publications
- Open Access
- 28 August 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1900651
Real-world anti-amyloid therapy beyond traditional symptomatic populations: a longitudinal case series
Introduction: Anti-amyloid monoclonal antibodies are approved as disease-modifying therapies for early Alzheimer’s disease (AD), but real-world evidence remains limited, particularly among individuals treated during preclinical or minimally symptomatic stages. This study characterized clinical and biomarker trajectories among anti-amyloid therapy recipients across disease stages. Method: We conducted a longitudinal retrospective case series of three biomarker-positive individuals from the Alzheimer’s Disease Neuroimaging Initiative who received lecanemab or donanemab. Clinical, cognitive, cerebrospinal fluid, plasma biomarker, and amyloid PET data were examined. Results: In all three cases, most of the observation period preceded anti-amyloid therapy initiation. Clinical trajectories varied by biomarker profile and treatment timing. Two participants received donanemab while cognitively normal or at an early transitional stage despite persistent amyloid- and tau-positive profiles. One participant received lecanemab after clinically significant impairment emerged. Cases 1 and 2 showed prolonged preservation of cognitive and functional performance despite sustained AD biomarker abnormalities and amyloid PET positivity. In case 2, age- and education-adjusted Wechsler Logical Memory testing detected progression to mild cognitive impairment despite preserved Mini-Mental State Examination and Clinical Dementia Rating scores. In contrast, case 3 showed persistent cognitive impairment and progression toward mild dementia. Conclusion: This case series illustrates substantial heterogeneity among real-world anti-amyloid therapy recipients. Persistent biomarker abnormalities may precede clinical decline for years, especially among highly educated individuals with substantial cognitive reserve. Conventional global screening tools may underestimate early decline and affect treatment eligibility decisions. Although not generalizable, these observations underscore the need for larger real-world studies characterizing clinical trajectories following anti-amyloid therapy.
- 28 August 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1900651
Open AccessReal-world anti-amyloid therapy beyond traditional symptomatic populations: a longitudinal case series
Introduction: Anti-amyloid monoclonal antibodies are approved as disease-modifying therapies for early Alzheimer’s disease (AD), but real-world evidence remains limited, particularly among individuals treated during preclinical or minimally symptomatic stages. This study characterized clinical and biomarker trajectories among anti-amyloid therapy recipients across disease stages. Method: We conducted a longitudinal retrospective case series of three biomarker-positive individuals from the Alzheimer’s Disease Neuroimaging Initiative who received lecanemab or donanemab. Clinical, cognitive, cerebrospinal fluid, plasma biomarker, and amyloid PET data were examined. Results: In all three cases, most of the observation period preceded anti-amyloid therapy initiation. Clinical trajectories varied by biomarker profile and treatment timing. Two participants received donanemab while cognitively normal or at an early transitional stage despite persistent amyloid- and tau-positive profiles. One participant received lecanemab after clinically significant impairment emerged. Cases 1 and 2 showed prolonged preservation of cognitive and functional performance despite sustained AD biomarker abnormalities and amyloid PET positivity. In case 2, age- and education-adjusted Wechsler Logical Memory testing detected progression to mild cognitive impairment despite preserved Mini-Mental State Examination and Clinical Dementia Rating scores. In contrast, case 3 showed persistent cognitive impairment and progression toward mild dementia. Conclusion: This case series illustrates substantial heterogeneity among real-world anti-amyloid therapy recipients. Persistent biomarker abnormalities may precede clinical decline for years, especially among highly educated individuals with substantial cognitive reserve. Conventional global screening tools may underestimate early decline and affect treatment eligibility decisions. Although not generalizable, these observations underscore the need for larger real-world studies characterizing clinical trajectories following anti-amyloid therapy.
- 1 December 2025
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 22 (3) , 451-458
Immigration timing modifies the association between medication non-adherence and cognitive function in older adults
- 1 December 2025
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 22 (3) , 451-458
Immigration timing modifies the association between medication non-adherence and cognitive function in older adults
- Open Access
- 28 May 2025
- Published by Elsevier in JAPhA Pharmacotherapy
- Vol. 2 (2)
Real-world safety profile of lecanemab: A disproportionality analysis of adverse events in the FDA adverse event reporting system
- 28 May 2025
- Published by Elsevier in JAPhA Pharmacotherapy
- Vol. 2 (2)
Open AccessReal-world safety profile of lecanemab: A disproportionality analysis of adverse events in the FDA adverse event reporting system
- Open Access
- 8 January 2021
- Published by University of Minnesota in INNOVATIONS in pharmacy
- Vol. 12 (1) , 21
The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection
Background: Proton pump inhibitors (PPIs) are among the most commonly used medications by patients due to its availability over the counter and frequent prescribing by physicians to treat and alleviate symptoms of gastroesophageal reflux disease. Recently, the FDA issued a warning with respect to the utilization of PPIs and risk of developing Clostridium difficile infections (CDI). The most commonly known medications to cause CDI are antibiotics. However, available studies suggest an association and increase in risk for CDI with PPI use as well. Objective: The purpose of this research is to review and summarize data currently available on the association between PPIs and CDI. Methods: To search for eligible studies, EBSCO engines were investigated using proton pump inhibitors or PPIs and Clostridium difficile or C. diff. as search terms. Meta analyses and systematic reviews published between 2000 and 2020 on adult patients were considered. Results: Eight meta-analyses and systematic reviews met the inclusion criteria. They included studies conducted in the US, Europe, Asia and Canada on inpatient and outpatient adults. The final result for all 8 studies showed a statistically significant association between PPIs and CDI ranging from mild to high risk. Conclusion: Currently available data suggest a positive association between PPIs and CDI.
- 8 January 2021
- Published by University of Minnesota in INNOVATIONS in pharmacy
- Vol. 12 (1) , 21
Open AccessThe Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection
Background: Proton pump inhibitors (PPIs) are among the most commonly used medications by patients due to its availability over the counter and frequent prescribing by physicians to treat and alleviate symptoms of gastroesophageal reflux disease. Recently, the FDA issued a warning with respect to the utilization of PPIs and risk of developing Clostridium difficile infections (CDI). The most commonly known medications to cause CDI are antibiotics. However, available studies suggest an association and increase in risk for CDI with PPI use as well. Objective: The purpose of this research is to review and summarize data currently available on the association between PPIs and CDI. Methods: To search for eligible studies, EBSCO engines were investigated using proton pump inhibitors or PPIs and Clostridium difficile or C. diff. as search terms. Meta analyses and systematic reviews published between 2000 and 2020 on adult patients were considered. Results: Eight meta-analyses and systematic reviews met the inclusion criteria. They included studies conducted in the US, Europe, Asia and Canada on inpatient and outpatient adults. The final result for all 8 studies showed a statistically significant association between PPIs and CDI ranging from mild to high risk. Conclusion: Currently available data suggest a positive association between PPIs and CDI.
- 1 July 2020
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 16 (7) , 982-986
Medication adherence among chronic condition patients in the Medicaid coverage gap
- 1 July 2020
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 16 (7) , 982-986
Medication adherence among chronic condition patients in the Medicaid coverage gap
- Open Access
- 17 July 2018
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 15 (7) , 1509
Shared Decision-Making and Women’s Adherence to Breast and Cervical Cancer Screenings
We examined the effect of shared decision-making (SDM) on women’s adherence to breast and cervical cancer screenings and estimated the prevalence and adherence rate of screenings. The study used a descriptive cross-sectional design using the 2017 Health Information National Trends Survey (HINTS) data collected by the National Cancer Institute. Adherence was defined based on the guidelines from the American Cancer Society and the composite measure of shared decision-making was constructed using three items in the data. Multivariable logistic regression was performed to examine the association between the SDM and adherence, controlling for cancer beliefs and socio-demographic variables. The analysis included 742 responses. Weighted to represent the U.S. population, 68.1% adhered to both breast and cervical cancer screening guidelines. The composite measure of SDM was reliable (α = 0.85), and a higher SDM score was associated with women’s screening adherence (b = 0.17; p = 0.009). There were still women who did not receive cancer screenings as recommended. The results suggest that the use of the SDM approach for healthcare professionals’ communication with patients can improve screening adherence.
- 17 July 2018
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 15 (7) , 1509
Open AccessShared Decision-Making and Women’s Adherence to Breast and Cervical Cancer Screenings
We examined the effect of shared decision-making (SDM) on women’s adherence to breast and cervical cancer screenings and estimated the prevalence and adherence rate of screenings. The study used a descriptive cross-sectional design using the 2017 Health Information National Trends Survey (HINTS) data collected by the National Cancer Institute. Adherence was defined based on the guidelines from the American Cancer Society and the composite measure of shared decision-making was constructed using three items in the data. Multivariable logistic regression was performed to examine the association between the SDM and adherence, controlling for cancer beliefs and socio-demographic variables. The analysis included 742 responses. Weighted to represent the U.S. population, 68.1% adhered to both breast and cervical cancer screening guidelines. The composite measure of SDM was reliable (α = 0.85), and a higher SDM score was associated with women’s screening adherence (b = 0.17; p = 0.009). There were still women who did not receive cancer screenings as recommended. The results suggest that the use of the SDM approach for healthcare professionals’ communication with patients can improve screening adherence.
- Open Access
- 11 July 2018
- Published by MDPI AG in Sustainability
- Vol. 10 (7) , 2419
Social Exclusion and Switching Barriers in Medicare Part D Choices
Previous studies have shown that Medicare beneficiaries do not tend to switch their prescription drug plans (Part D), even though they can greatly save on the money spent on drugs by switching plans. To explore this occurrence, the present study focused on the concept of social exclusion—one of the most important characteristics prevalent in the elderly. This study compared the impact of two types of social exclusion on the association between psychological cost and plan switching: active (or rejected) social exclusion and passive (or ignored) social exclusion. The study’s aim was to examine the moderating effect of social exclusion on the relationship between the cost of switching and willingness to switch plan to build sustainable health care system. The Prescription Drug Study supplementary to the Health and Retirement Study (HRS) data were utilized for analysis by applying a Hierarchical Linear Model (HLM) (N = 1042). The findings suggest that active social exclusion moderates the relationship between the switching cost and willingness to switch plan. This study’s findings will help policymakers better understand the elderly’s decision-making process pertaining to plans and promote their informed plan decisions to build sustainable health care system.
- 11 July 2018
- Published by MDPI AG in Sustainability
- Vol. 10 (7) , 2419
Open AccessSocial Exclusion and Switching Barriers in Medicare Part D Choices
Previous studies have shown that Medicare beneficiaries do not tend to switch their prescription drug plans (Part D), even though they can greatly save on the money spent on drugs by switching plans. To explore this occurrence, the present study focused on the concept of social exclusion—one of the most important characteristics prevalent in the elderly. This study compared the impact of two types of social exclusion on the association between psychological cost and plan switching: active (or rejected) social exclusion and passive (or ignored) social exclusion. The study’s aim was to examine the moderating effect of social exclusion on the relationship between the cost of switching and willingness to switch plan to build sustainable health care system. The Prescription Drug Study supplementary to the Health and Retirement Study (HRS) data were utilized for analysis by applying a Hierarchical Linear Model (HLM) (N = 1042). The findings suggest that active social exclusion moderates the relationship between the switching cost and willingness to switch plan. This study’s findings will help policymakers better understand the elderly’s decision-making process pertaining to plans and promote their informed plan decisions to build sustainable health care system.
- Open Access
- 19 June 2018
- Published by Springer Nature in BMC Health Services Research
- Vol. 18 (1) , 1-7
Variability of assister availability in health insurance marketplace in the U.S.
The Affordable Care Act (ACA) established the health insurance marketplaces to provide people the opportunity to obtain healthcare coverage. Assisters have worked with people who may have difficulty understanding the new system and selecting the right plan. This study aims to describe the local availability of assister programs, and examine the factors influencing assister provision. The 2016 Small Area Health Insurance Estimates data and a database of assister programs constructed using healthcare.gov were analyzed at the county level. Bivariate analysis by assister provision was performed to determine the differences between the two groups, and the hierarchical generalized linear model was used to examine the factors predicting assister availability. The study analyzed 2260 counties nested within 35 states. Assister availability largely varied across counties and states. About half of the counties did not provide assisters at all, and the assister provision rate at state level ranged between 19 - 100%. Counties in metropolitan areas were more likely to provide assister programs than rural areas, and so were counties with higher adult uninsured rate or higher uninsured rate among the people with incomes between 138 - 400% of federal poverty level (FPL). Despite the important role of in-person assistance in plan enrollment, no previous study has examined the local variability of assister program. Our study found a large geographical variation in assister availability, raising concerns about the disparity in access to assister service.
- 19 June 2018
- Published by Springer Nature in BMC Health Services Research
- Vol. 18 (1) , 1-7
Open AccessVariability of assister availability in health insurance marketplace in the U.S.
The Affordable Care Act (ACA) established the health insurance marketplaces to provide people the opportunity to obtain healthcare coverage. Assisters have worked with people who may have difficulty understanding the new system and selecting the right plan. This study aims to describe the local availability of assister programs, and examine the factors influencing assister provision. The 2016 Small Area Health Insurance Estimates data and a database of assister programs constructed using healthcare.gov were analyzed at the county level. Bivariate analysis by assister provision was performed to determine the differences between the two groups, and the hierarchical generalized linear model was used to examine the factors predicting assister availability. The study analyzed 2260 counties nested within 35 states. Assister availability largely varied across counties and states. About half of the counties did not provide assisters at all, and the assister provision rate at state level ranged between 19 - 100%. Counties in metropolitan areas were more likely to provide assister programs than rural areas, and so were counties with higher adult uninsured rate or higher uninsured rate among the people with incomes between 138 - 400% of federal poverty level (FPL). Despite the important role of in-person assistance in plan enrollment, no previous study has examined the local variability of assister program. Our study found a large geographical variation in assister availability, raising concerns about the disparity in access to assister service.
- Open Access
- 25 April 2018
- Published by University of Minnesota in INNOVATIONS in pharmacy
- Vol. 9 (2) , 7
Perceived Value of Health Insurance and Enrollment Decision among Low-Income Population
The individual mandate is one of the key features of the Affordable Care Act (ACA) and has contributed to a substantial decrease in the overall uninsured rate. We examined the relationship between the individual’s insurance status and his/her attitude towards risk and uncertainty among the nonelderly adults, without employer-sponsored insurance (ESI) sources and who are most likely to benefit from the ACA. A descriptive, cross-sectional study was conducted using the 2014 full-year consolidated data file from the Household Component of the Medical Expenditure Panel Survey-Household Component (MEPS-HC). This study included 4,848 individuals, aged 18–64 years, with incomes between 138–400 % of the Federal Poverty Level (FPL), and without access to public coverage or ESI. We examined the factors associated with the likelihood of being uninsured using a logit model. We found that the proportion of the uninsured among the low-income nonelderly adults without ESI (31.1%) was much higher than the one among the nonelderly adults (14.3%). The uninsured adults were likely to have lower demand for insurance and perceived value of insurance and were less likely to visit a doctor or to fill prescription drugs. More rigorous outreach efforts focusing on increasing perceived value of health insurance could contribute to an increased insurance coverage among low-income populations. Type: Original Research
- 25 April 2018
- Published by University of Minnesota in INNOVATIONS in pharmacy
- Vol. 9 (2) , 7
Open AccessPerceived Value of Health Insurance and Enrollment Decision among Low-Income Population
The individual mandate is one of the key features of the Affordable Care Act (ACA) and has contributed to a substantial decrease in the overall uninsured rate. We examined the relationship between the individual’s insurance status and his/her attitude towards risk and uncertainty among the nonelderly adults, without employer-sponsored insurance (ESI) sources and who are most likely to benefit from the ACA. A descriptive, cross-sectional study was conducted using the 2014 full-year consolidated data file from the Household Component of the Medical Expenditure Panel Survey-Household Component (MEPS-HC). This study included 4,848 individuals, aged 18–64 years, with incomes between 138–400 % of the Federal Poverty Level (FPL), and without access to public coverage or ESI. We examined the factors associated with the likelihood of being uninsured using a logit model. We found that the proportion of the uninsured among the low-income nonelderly adults without ESI (31.1%) was much higher than the one among the nonelderly adults (14.3%). The uninsured adults were likely to have lower demand for insurance and perceived value of insurance and were less likely to visit a doctor or to fill prescription drugs. More rigorous outreach efforts focusing on increasing perceived value of health insurance could contribute to an increased insurance coverage among low-income populations. Type: Original Research